European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetine lilly is indicated in adults for:treatment of major depressive disordertreatment of diabetic peripheral neuropathic paintreatment of generalised anxiety disorderduloxetine lilly is indicated in adults.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - capsules - see ingredients - capsule fluoxetine hydrochloride 22,36 mg

European Union - English - EMA (European Medicines Agency)

eli lilly netherlands - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - erectile dysfunction - urologicals - treatment of erectile dysfunction in adult males.in order for tadalafil to be effective, sexual stimulation is required.tadalafil lilly is not indicated for use by women.treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; hypromellose; lactose monohydrate; carnauba wax; crospovidone; magnesium stearate; propylene glycol; ethanol; indigo carmine; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; colour - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; carnauba wax; hyprolose; microcrystalline cellulose; crospovidone; lactose monohydrate; hypromellose; propylene glycol; indigo carmine; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; colour - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; carnauba wax; microcrystalline cellulose; crospovidone; hypromellose; hyprolose; colour; propylene glycol; indigo carmine; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: carnauba wax; crospovidone; lactose monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate; hyprolose; propylene glycol; indigo carmine; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; colour - zyprexa is indicated for the treatment of schizophrenia and related psychoses. zyprexa alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. zyprexa is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 50 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 3350; iron oxide yellow; iron oxide red; polyvinyl alcohol; sodium stearylfumarate; lactose monohydrate; purified talc; microcrystalline cellulose; silicon dioxide; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; purified talc; iron oxide yellow; silicon dioxide; polyvinyl alcohol; macrogol 3350; sodium stearylfumarate; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.